DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Caverject Impulse (Alprostadil) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Local Adverse Reactions

The following local adverse reaction information was derived from controlled and uncontrolled studies of CAVERJECT Sterile Powder, including an uncontrolled 18-month safety study.

Local Adverse Reactions Reported by ≥ 1% of Patients Treated with CAVERJECT Sterile Powder for up to 18 MonthsExcept for penile pain (2%), no significant local adverse reactions were reported by 294 patients who received 1 to 3 injections of placebo.
Event CAVERJECT
N = 1861
Penile pain 37%
Prolonged erection 4%
Penile fibrosisSee General Precautions. 3%
Injection site hematoma 3%
Penis disorderIncludes numbness, yeast infection, irritation, sensitivity, phimosis, pruritus, erythema, venous leak, penile skin tear, strange feeling of penis, discoloration of penile head, itch at tip of penis. 3%
Injection site ecchymosis 2%
Penile rash 1%
Penile edema 1%

Penile Pain

Penile pain after intracavernosal administration of CAVERJECT was reported at least once by 37% of patients in clinical studies of up to 18 months in duration. In the majority of the cases, penile pain was rated mild or moderate in intensity. Three percent of patients discontinued treatment because of penile pain. The frequency of penile pain was 2% in 294 patients who received 1 to 3 injections of placebo.

Prolonged Erection/Priapism

In clinical trials, prolonged erection was defined as an erection that lasted for 4 to 6 hours; priapism was defined as erection that lasted 6 hours or longer. The frequency of prolonged erection after intracavernosal administration of CAVERJECT was 4%, while the frequency of priapism was 0.4% (see WARNINGS).

Hematoma/Ecchymosis

The frequency of hematoma and ecchymosis was 3% and 2%, respectively. In most cases, hematoma/ecchymosis was judged to be a complication of a faulty injection technique. Accordingly, proper instruction of the patient in self-injection is of importance to minimize the potential of hematoma/ecchymosis (see DOSAGE AND ADMINISTRATION).

The following local adverse reactions were reported by fewer than 1% of patients after injection of CAVERJECT: balanitis, injection site hemorrhage, injection site inflammation, injection site itching, injection site swelling, injection site edema, urethral bleeding, penile warmth, numbness, yeast infection, irritation, sensitivity, phimosis, pruritus, erythema, venous leak, painful erection, and abnormal ejaculation.

Systemic Adverse Events

The following systemic adverse event information was derived from controlled and uncontrolled studies of CAVERJECT Sterile Powder, including an uncontrolled 18-month safety study.

Systemic Adverse Events Reported by ≥ 1% of Patients Treated with CAVERJECT Sterile Powder for up to 18 MonthsNo significant adverse events were reported by 294 patients who received 1 to 3 injections of placebo.
Body System/Reaction CAVERJECT
N = 1861
Cardiovascular System
  Hypertension 2%
Central Nervous System
  Headache 2%
  Dizziness 1%
Musculoskeletal System
  Back pain 1%
Respiratory System
  Upper respiratory infection 4%
  Flu syndrome 2%
  Sinusitis 2%
  Nasal congestion 1%
  Cough 1%
Urogenital System
  Prostatic DisorderProstatitis, pain, hypertrophy, enlargement 2%
Miscellaneous
  Localized painPain in various anatomical structures other than injection site 2%
  TraumaInjuries, fractures, abrasions, lacerations, dislocations 2%

The following systemic events, which were reported for < 1% of patients in clinical studies, were judged by investigators to be possibly related to use of CAVERJECT: testicular pain, scrotal disorder, scrotal edema, hematuria, testicular disorder, impaired urination, urinary frequency, urinary urgency, pelvic pain, hypotension, vasodilation, peripheral vascular disorder, supraventricular extrasystoles, vasovagal reactions, hypesthesia, non-generalized weakness, diaphoresis, rash, non-application site pruritus, skin neoplasm, nausea, dry mouth, increased serum creatinine, leg cramps, and mydriasis.

Hemodynamic changes, manifested as decreases in blood pressure and increases in pulse rate, were observed during clinical studies, principally at doses above 20 mcg and above 30 mcg of alprostadil, respectively, and appeared to be dose-dependent. However, these changes were usually clinically unimportant; only three patients discontinued the treatment because of symptomatic hypotension.

CAVERJECT had no clinically important effect on serum or urine laboratory tests.

The safety of CAVERJECT IMPULSE was evaluated in a study that compared the formulation of alprostadil for injection contained in CAVERJECT IMPULSE with the formulation contained in CAVERJECT Sterile Powder. The doses used by the 87 patients in this crossover study were the same for both formulations. The number and type of events reported for CAVERJECT IMPULSE were consistent between formulations in this study and in other controlled and uncontrolled studies with CAVERJECT Sterile Powder.

Post-Marketing Surveillance

The following additional adverse reactions have been reported: device malfunction/failure, drug ineffective and drug effect decreased.



REPORTS OF SUSPECTED CAVERJECT IMPULSE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Caverject Impulse. The information is not vetted and should not be considered as verified clinical evidence.

Possible Caverject Impulse side effects / adverse reactions in 46 year old male

Reported by a consumer/non-health professional from Denmark on 2011-10-06

Patient: 46 year old male weighing 71.0 kg (156.2 pounds)

Reactions: Drug Effect Increased, Drug Ineffective, Erection Increased

Suspect drug(s):
Caverject Impulse
    Dosage: 5 ug, unk

Caverject Impulse
    Dosage: 2.5 ug, unk

Other drugs received by patient: Actrapid; Levemir; Ramipril



Possible Caverject Impulse side effects / adverse reactions in 46 year old male

Reported by a consumer/non-health professional from Denmark on 2011-10-06

Patient: 46 year old male weighing 71.0 kg (156.2 pounds)

Reactions: Drug Ineffective, Drug Effect Increased, Erection Increased

Suspect drug(s):
Caverject Impulse
    Dosage: 5 ug, unk

Caverject Impulse
    Dosage: 2.5 ug, unk

Other drugs received by patient: Actrapid; Ramipril; Levemir



Possible Caverject Impulse side effects / adverse reactions in 75 year old male

Reported by a physician from Germany on 2011-11-18

Patient: 75 year old male weighing 90.0 kg (198.0 pounds)

Reactions: Prostatic Specific Antigen Increased, Drug Ineffective

Suspect drug(s):
Caverject Impulse



See index of all Caverject Impulse side effect reports >>

Drug label data at the top of this Page last updated: 2013-12-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017